Prostate cancer is the second most common cancer worldwide and the sixth cause of cancer-related death in men. When hormone
therapy fails to control tumour growth, castration-resistant prostate cancer (CRPC) occurs and chemotherapy drugs must be administered.
Since 2004, docetaxel administration is the standard of care in metastatic CRPC, although it presents severe limitations such as
acquired resistance and poor prognosis. An analogue (cabazitaxel) was approved by the FDA in 2010 as a second-line chemotherapeutic
agent. Novel immuno- and hormonal therapy agents, as well as tumour vaccines, have been recently developed, but new strategies are
still needed for effectively handling this type of neoplasia. Platinum compounds, in particular, have been the object of a growing interest,
despite the former belief that they should have modest activity against prostate cancer. Compounds such as carboplatin, oxaliplatin or satraplatin,
either alone or in combination, have lately shown promising results. In order to overcome the deleterious side-effects usually
associated to these metal-based agents, several approaches have been followed with a view to optimise drug delivery and targeting, some
of which showed considerable success in CRPC. Platinum drugs may therefore have an important role in the chemotherapeutic management
of human metastatic castration-resistant prostate cancer, mostly in second-line strategies. The present review addresses the most
relevant studies on platinum-based antineoplastic agents towards CRPC in the last decade – from first- and second-generation complexes
to newly developed compounds.
Keywords: Castration-resistant prostate cancer (CRPC), metastasis, chemotherapy, platinum agents, cisplatin, carboplatin, oxaliplatin, picoplatin,
satraplatin, single administration, combined administration, targeted delivery.
Rights & PermissionsPrintExport